uniQure N.V. Stock Prediction
AI-powered sentiment analysis and prediction trends for QURE, updated each market day.
QURE AI Sentiment
AI predicts uniQure N.V. stock is likely to increase over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Sector
Exchange
Market Cap
$3,084,724,341
Cap Tier
Employees
221
Headquarters
AMSTERDAM
Listed Since
Feb. 5, 2014
Website
QURE Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
QURE Volatility
uniQure N.V. has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
